TY - JOUR
T1 - Ebselen improves ischemia-reperfusion injury after rat lung transplantation
AU - Hamacher, Jürg
AU - Stammberger, Uz
AU - Weber, Elvira
AU - Lucas, Rudolf
AU - Wendel, Albrecht
N1 - Funding Information:
This work was supported by the Deutsche Forschungsgemeinschaft (FOR 321/2-1; research group “Endogenous tissue injury: Mechanisms of autodestruction”).
PY - 2009/4
Y1 - 2009/4
N2 - The heterocyclic organic compound ebselen (2-phenyl-1,2-benizsoselenazol- 3(2H)-one) is a glutathione peroxidase mimick with protective properties against oxidative injury. Ebselen also has anti-inflammatory activity, including attenuation of tumor necrosis factor release and increase of interleukin-10, as shown in vivo, in inflammatory and ischemia-reperfusion injuries, including those of the lung. This study was designed to assess its effect on severe ischemia-reperfusion injury in a model of left-sided rat lung isotransplantation. Orthotopic single left-sided lung allotransplantation (Wistar to Wistar) was performed in female rats after a total ischemic time of 18 h. In nine recipients given 500 mg/kg oral ebselen 1 h before transplantation, graft PaO2/FiO2 was improved 24 h after transplantation, as evidenced with a mean (standard deviation) PaO2 of 139 (61) mmHg vs. eight controls with 65 (33) mmHg (p = 0.009). Bronchoalveolar PMN count was reduced to approximately 50% in the ebselen group compared with controls, whereas no difference in the tumor necrosis factor content was found. We conclude that the improvement of lung function in ebselen-treated transplanted rats is mainly the result of the anti-inflammatory activity of the drug during reperfusion.
AB - The heterocyclic organic compound ebselen (2-phenyl-1,2-benizsoselenazol- 3(2H)-one) is a glutathione peroxidase mimick with protective properties against oxidative injury. Ebselen also has anti-inflammatory activity, including attenuation of tumor necrosis factor release and increase of interleukin-10, as shown in vivo, in inflammatory and ischemia-reperfusion injuries, including those of the lung. This study was designed to assess its effect on severe ischemia-reperfusion injury in a model of left-sided rat lung isotransplantation. Orthotopic single left-sided lung allotransplantation (Wistar to Wistar) was performed in female rats after a total ischemic time of 18 h. In nine recipients given 500 mg/kg oral ebselen 1 h before transplantation, graft PaO2/FiO2 was improved 24 h after transplantation, as evidenced with a mean (standard deviation) PaO2 of 139 (61) mmHg vs. eight controls with 65 (33) mmHg (p = 0.009). Bronchoalveolar PMN count was reduced to approximately 50% in the ebselen group compared with controls, whereas no difference in the tumor necrosis factor content was found. We conclude that the improvement of lung function in ebselen-treated transplanted rats is mainly the result of the anti-inflammatory activity of the drug during reperfusion.
KW - Anti-inflammatory agents
KW - Ebselen
KW - Lung transplantation
KW - Reperfusion injury
UR - http://www.scopus.com/inward/record.url?scp=67649130167&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67649130167&partnerID=8YFLogxK
U2 - 10.1007/s00408-009-9134-x
DO - 10.1007/s00408-009-9134-x
M3 - Article
C2 - 19198941
AN - SCOPUS:67649130167
SN - 0341-2040
VL - 187
SP - 98
EP - 103
JO - Lung
JF - Lung
IS - 2
ER -